Thus, for IDH1-mutant AML, one may consider using IDH1-inhibitors rather than HMA + VEN, while for the IDH2-mutant disease, perhaps the use of HMA + VEN may be more likely to offer clinical benefits. The gene discussed is IDH1; the disease is acute myeloid leukemia.